Day: March 14, 2025

MRC Global Reports Full Year and Fourth Quarter 2024 Results

Written by Customer Service on March 14, 2025. Posted in Earnings Releases And Operating Results.

HOUSTON, March 14, 2025 (GLOBE NEWSWIRE) — MRC Global Inc. (NYSE: MRC) today reported full year and fourth quarter 2024 results. Full Year 2024 Financial Highlights: ● Operating cash flows from continuing operations of $268 million, highest since 2015 ● Sales of $3,011 million ● Net income from continuing operations of $78 million ● Adjusted EBITDA of $202 million, 6.7% of sales ● Gross profit, as a percentage of sales, of 20.6% ● Adjusted Gross Profit, as a percentage of sales, of 21.9% and the third consecutive year above 21% ● Net Debt of $324 million, a 1.6x net debt leverage ratio Fourth Quarter 2024 Financial Highlights: ● Operating cash flows from continuing operations of $73 million ● Sales of $664 million ● Net loss from continuing operations of ($1) million ● Adjusted EBITDA of $32 million, or 4.8% of sales ● Gross profit,...

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Written by Customer Service on March 14, 2025. Posted in Public Companies.

– Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study –– Company expects to submit New Drug Application (NDA) in April 2025 – DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced positive results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the U.S. Food and Drug Administration (FDA)-approved reference product of the same active ingredient. Healthy adults...

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

Written by Customer Service on March 14, 2025. Posted in Public Companies.

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME) ANI plans to begin marketing ILUVIEN in the U.S. under the combined label later this yearBAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also includes other updates to the label including to the Warnings and Precautions section. As previously announced, the Company plans to market ILUVIEN for chronic...

Dundee Precious Metals Announces Renewal of Normal Course Issuer Bid

Written by Customer Service on March 14, 2025. Posted in Public Companies.

TORONTO, March 14, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (the “Company”) announced today that the Toronto Stock Exchange (“TSX”) accepted its notice of intention to renew its normal course issuer bid (the “New Bid”) to purchase certain of its common shares (“Shares”) through the facilities of the TSX. The Company commenced a normal course issuer bid (the “Previous Bid”) on March 18, 2024, which will terminate on March 17, 2025. Under the Previous Bid, the Company sought and obtained approval to purchase up to 15.5 million Shares, representing approximately 9.8% of its public float as of March 6, 2024. As of February 28, 2025, the Company has repurchased 11,028,569 Shares under the Previous Bid through the TSX or other alternative trading systems or by such other means as permitted by the TSX and applicable...

AirSculpt Technologies Reports Fourth Quarter, and Full Year Fiscal 2024 Results

Written by Customer Service on March 14, 2025. Posted in Earnings Releases And Operating Results.

MIAMI BEACH, Fla., March 14, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2024. “Following a challenging 2024, I am eager to help write the next chapter for AirSculpt and focus on setting a strategy, implementing business processes and developing a culture that delivers meaningful value for our shareholders,” stated Yogi Jashnani, Chief Executive Officer. “AirSculpt possesses many strengths given its proprietary method, its successful track record of providing more than 70,000 minimally invasive body contouring procedures and its international footprint with 32 centers in operation.” “While we anticipate facing a tough year-over-year comparison...

Pilgrim’s Announces $1.5 Billion Special Dividend and Long-term Capital Allocation Strategy

Written by Customer Service on March 14, 2025. Posted in Dividend Reports And Estimates.

Company Outlines Portfolio Enhancements, Brand Growth at Investor Day in New York GREELEY, Colo., March 14, 2025 (GLOBE NEWSWIRE) — Pilgrim’s Pride Corporation (NASDAQ: PPC), one of the world’s leading food companies, today announced a capital deployment strategy in support of its ongoing efforts to improve its capital structure, enhance its diversified portfolio, stimulate brand growth and generate shareholder value. As a part of the strategy, the company’s board of directors has approved the declaration of a special cash dividend of $6.30 per share. The total amount of the special dividend payment will be approximately $1.5 billion, based on the current number of shares outstanding. The special cash dividend is payable on April 17, 2025, to stockholders of record on April 3, 2025. “Pilgrim’s is confident in the future of our...

Form 8 (OPD) – Kenmare Resources plc

Written by Customer Service on March 14, 2025. Posted in Mergers And Acquisitions.

FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION(a) Full name of discloser: Kenmare Resources plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Kenmare Resources plc(d) Is the discloser the offeror or the offeree? OFFEREE(e) Date position held: The latest practicable date prior to the disclosure 13 March 2025(f) In...

Pioneering Autonomous Technology Drives Global Expansion and Commercial Market Growth

Written by Customer Service on March 14, 2025. Posted in Earnings Releases And Operating Results.

WeRide Announces Unaudited Financial Results for the Fourth Quarter and Full Year 2024 NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) — WeRide Inc. (Nasdaq: WRD) (“WeRide” or the “Company”), a global leader in autonomous driving technology, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights WeRide continues to enhance its global market presence through thoughtful market entries and strategic expansions in Europe, the Middle East and Asia. These efforts are all made possible by the Company’s continuous technological innovation and operational expertise, both key to its leadership in autonomous driving. In 2024, WeRide achieved record-high robotaxi revenue and the strongest international revenue since the company’s inception. WeRide Continues Technology Innovation...

Offentliggørelse af årsrapport for 2024

Written by Customer Service on March 14, 2025. Posted in Public Companies.

Bestyrelsen for Kapitalforeningen BLS Invest har dags dato godkendt foreningens årsrapport for 2024. Afdeling Globale Aktier KL og afdeling Globale Aktier Akk. gav begge et afkast på 10,5 % efter alle omkostninger og inklusive geninvesterede udbytter. Afdeling Danske Aktier KL og afdeling Danske Aktier Akk. gav begge et afkast på 4,4 % De af bestyrelsen indstillede udbytter på kr. 108,00 pr. andel i afdeling Globale Aktier KL og kr. 115,00 pr. andel i afdeling Danske Aktier KL blev udbetalt til investorerne den 24. januar 2025. Årsrapporten 2024 er vedhæftet og kan tillige findes på foreningens hjemmeside www.blsinvest.dk Eventuelle henvendelser vedrørende denne meddelelse kan rettes til foreningens bestyrelsesformand, Chris Bigler, på tlf. 29 74 06 55.Med venlig hilsen Kapitalforeningen BLS InvestAttachmentKapitalforeningen...

Li Auto Inc. Announces Unaudited Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 14, 2025. Posted in Earnings Releases And Operating Results.

Quarterly total revenues reached RMB44.3 billion (US$6.1 billion)1Quarterly deliveries reached 158,696 vehiclesFull year total revenues reached RMB144.5 billion (US$19.8 billion)Full year deliveries were 500,508 vehicles BEIJING, China, March 14, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced its unaudited financial results for the quarter and full year ended December 31, 2024. Operating Highlights for the Fourth Quarter of 2024 and Full Year 2024Total deliveries for the fourth quarter of 2024 were 158,696 vehicles, representing a 20.4% year-over-year increase.Total deliveries for the full year 2024 reached 500,508 vehicles, representing an increase of 33.1% from 376,030 vehicles in 2023. FY 2024 2024 Q4 2024 Q3 2024 Q2 2024 Q1Deliveries 500,508 158,696 152,831 108,581 80,400 FY...

Day: March 14, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals